Clinical Significance of Platelet Allo-antibodies.

血小板同种抗体的临床意义。

• 批准号: 06454617
• 负责人: SHIBATA Yoichi
• 金额: $ 4.42万
• 依托单位: University of Tokyo
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (B)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 1995
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-06454617/
• 关键词: Platelet Allo-antigen; Platelet Allo-antibody; Platelet Transfusion; Neonatal Alliommune Thrombocytopenia; 血小板型(HPA); 新生児血小板減少症柴斑病; 血小板輸血不応答

1) We were unable to detect Mo^a, Sr^a or Va^a antigens among Japanese using our platelet-panel. In contrast, about 5% (15/314) were found to be Tu^a positive.2) We have experienced 29 cases of NAIT (Neonatal Alloimmune Thrombocytopenia) : 20 cases due to anti-HPA-4b (YuK^a) antibodies, 3 cases due to anti-HPA-4a (Yuk^b), 5 cases due to anti-HPA-3a (Bak^a) and 1 case due to anti-HPA-5b (Br^a). Among them 3 cases were complicated with intracranial hemorrhage.3) By screening a large number of samples, we found that anti-HPA-2b (Sib^a) playd an important role in the case of platelet transfusion refractoriness.4) The MPHA (mixed passive hemagglutination) method was developed about 15 years ago as a simple and sensitive test for the detection of anti-platelet antibodies. It has been refined now. Using 5% sucrose, the platelet-fixed plate can be kept frozen (below-40 C) without loss of reactivities for more than a year. Thus, MPHA should be employed as the routine test in any lab in the hospital for the detection of platelet allo-antibodies.

1)我们用我们的血小板板未能检测到日本人的Mo^a、sr^a或Va^a抗原。新生儿异基因免疫性血小板减少症29例，其中抗HPA-4b抗体阳性20例，抗HPA-4a抗体阳性3例，抗HPA-3a抗体阳性5例，抗HPA-5b抗体阳性1例。3)通过对大量标本的筛选，发现抗-HPA-2b(Sib^a)在血小板输注无效的病例中起重要作用。4)MPHA(混合被动血凝法)是大约15年前发展起来的一种简便、敏感的抗血小板抗体检测方法。它现在已经被提炼了。使用5%的蔗糖，血小板固定板可以保持冷冻(低于-40摄氏度)一年以上不失去反应性。因此，MPHA应作为医院任何实验室检测血小板同种抗体的常规检测方法。

项目成果

Fujiwara K.et al.: "DNA-Based Typing of Human Platelet Antigen Systems by PCR-SSCP(Single-Strand Conformation Polymorphism)Method." Vox Sang. 69. 347-351 (1995)

Fujiwara K.等人：“通过 PCR-SSCP（单链构象多态性）方法对人类血小板抗原系统进行 DNA 分型。”

Araki N et al: "Anti-HLA Antibody Screeing with Platelet Soluble HLA Antigens by MPHA Method." VOX Sang. 69. 222-230 (1995)

Araki N 等人：“通过 MPHA 方法用血小板可溶性 HLA 抗原筛选抗 HLA 抗体。”

Tanaka S., Taniue A., Nagao N., Ohnoki S., Tomita T., Shibata H., Okubo Y., Yamaguchi H., Shibata Y.: "Genotype frequencies of the human platelet antigen, Ca/Tu, in Japanese, determined by a PCR-RFLP method" Vox Sang. 70. 40-44 (1996)

Tanaka S.、Taniue A.、Nagao N.、Ohnoki S.、Tomita T.、Shibata H.、Okubo Y.、Yamaguchi H.、Shibata Y.：“人类血小板抗原 Ca/Tu 的基因型频率，

Lin M et al: "Neonatal Alloimmune Thrombocytopenia in Taiwan Due to an Antibody against a Labile Component of HPA-3a(Bak^a)" VOX Sanginis. 69. 336-340 (1995)

Lin M 等人：“台湾新生儿同种免疫血小板减少症因针对 HPA-3a(Bak^a) 不稳定成分的抗体而引起”VOX Sanginis。

Matsui K., Ohsaki E., Goto A., Koresawa M., Kigasawa Y., Shibata Y.: "Perinatal Intracranial Hemorrhage due to Severe Neonatal Alloimmune Thrombocytopenic Purpura (NAITP) Associated with Anti-Yuk^b (HPA-4a) Antibodies." Brain and Development. 17. 352-355

Matsui K.、Ohsaki E.、Goto A.、Koresawa M.、Kigasawa Y.、Shibata Y.：“与抗 Yuk^b (HPA-4a) 相关的严重新生儿同种免疫性血小板减少性紫癜 (NAITP) 导致的围产期颅内出血